| Amifostine | |
| |
| Identification | |
|---|---|
| Nom UICPA | S-{2-[(3-aminopropyl)amino]éthyl} dihydrogénophosphorothioate |
| No CAS | |
| NoECHA | 100.161.827 |
| Code ATC | V03 |
| SMILES |
|
| InChI |
|
| Propriétés chimiques | |
| Formule |
C5H15N2O3PS [Isomères] |
| Masse molaire | 214,223 ± 0,011 g/mol C 28,03 %, H 7,06 %, N 13,08 %, O 22,41 %, P 14,46 %, S 14,97 %, |
| Unités du SI et CNTP, sauf indication contraire. | |
modifier 
|
|
L'amifostine est un adjuvant cytoprotecteur utilisé en chimiothérapie du cancer impliquant des agents chimiothérapeutiques liant l'ADN.
Texte anglais à traduire :
Amifostine is used therapeutically to reduce the incidence of neutropenia-related fever and infection induced by DNA-binding chemotherapeutic agents including alkylating agents (e.g. cyclophosphamide) and platinum-containing agents (e.g. cisplatin). It is also used to decrease the cumulative nephrotoxicity associated with platinum-containing agents. Amifostine is also indicated to reduce the incidence of xerostomia in patients undergoing radiotherapy for head and neck cancer.
Amifostine is an organic thiophosphate prodrug which is dephosphorylated in vivo by alkaline phosphatase to the active cytoprotective thiol metabolite. The selective protection of non-malignant tissues is believed to be due to higher alkaline phosphatase activity, higher pH, and vascular permeation of normal tissues.
Spécialités
- Ethyol
